Scott D. Patterson, Ph.D.

Executive Director, Medical Sciences
Amgen Inc.

Dr. Patterson is an Executive Director in Medical Sciences at Amgen and has for the past decade been involved in translational research, applying biomarkers for pharmacodynamic assessments and ultimately patient selection. He formed and led the Amgen's successful biomarker program as Molecular Sciences head from 2004-2012 and now heads the Medical Sciences-In Vitro Diagnostic Group, responsible for the transition of biomarkers to IVDs. This role encompasses the identification, implementation and management of diagnostic partnering strategies for all Amgen therapeutics (e.g., the development of KRAS and then RAS as a predictive biomarkers and companion diagnostic for Vectibix® therapy). These efforts do not end at successful regulatory filing of the diagnostic in the regions in which the therapeutic is marketed, but where possible extend to enabling ongoing quality assessment of these biomarker assessments. He has published extensively in the field of proteomics and biomarkers, holds editorial board positions and is a frequent guest lecturer. He was previously Vice President of Proteomics at the Celera Genomics Group and the Chief Scientific Officer of Farmal Biomedicines, LLC. While at Celera, he established the company's initial foray into identification of cell surface targets for oncology, a number of which have been licensed. Dr. Patterson was at Amgen from 1993–2000 ultimately leading the Department of Biochemistry and Genetics. His academic career, encompassing work on analytical protein chemistry applications and apoptosis, began at The University of Queensland where he received his Ph.D. and B.Sc. and held research positions of increasing responsibility to that of Chief Scientific Officer. In 1991 he joined the faculty of Cold Spring Harbor Laboratory, New York.